-
-
ORKAMBI
- QTY 112
- 200-125MG
- Tablet
- Near 77381
LUMACAFTOR; IVACAFTOR (LOO ma KAF tor; EYE va KAF tor) treats cystic fibrosis (CF). It works by helping your body balance the level of salt and water in your lungs. This prevents the buildup of mucus and reduces the symptoms of CF.
Change Location
Set Price Drop Alert for:
ORKAMBI
- QTY 112
- 200-125MG
- Tablet
What does Supply mean?
If your selected quantity is intended to last longer than one month, please recheck the price using the 3-months supply option. In some cases, the estimated drug price may vary depending on the supply duration.
More Ways to Save On:
ORKAMBI
- QTY 112
- 200-125MG
- Tablet
You may find alternative ways to save with this medication. Talk to your pharmacist about the potential option(s) noted below.
Change Form
Medicine Chest
ORKAMBI Lifestyle Interactions
-
Lumacaftor 200mg, Ivacaftor 125mg, Oral tablet
• Interaction: Grapefruit juice• Severity: Major• Notes for Consumers: Do not take Ivacaftor and grapefruit juice or Seville oranges together. Grapefruit juice and Seville oranges may increase the amount of Ivacaftor in your blood. Side effects from Ivacaftor may get worse if you use grapefruit juice or Seville oranges. Notify your prescriber if you have any new or worsening side effects.• Notes for Professionals: The manufacturer recommends avoiding grapefruit or Seville oranges during ivacaftor therapy because ivacaftor exposure may be increased. Ivacaftor is a CYP3A substrate. Grapefruit juice and Seville oranges contain components that inhibit CYP3A, and therefore, may reduce ivacaftor metabolism. -
Lumacaftor 200mg, Ivacaftor 125mg, Oral tablet
• Interaction: Cannabis• Severity: Major• Notes for Consumers: Discuss cannabis use with your care team. The effects of cannabis may be altered if used with your medication.• Notes for Professionals: Advise patients to avoid cannabis use during lumacaftor; ivacaftor treatment. Concomitant use may decrease the concentration of some cannabinoids and alter their effects. The cannabinoids delta-9-tetrahydrocannabinol (THC) and cannabidiol (CBD) are CYP3A substrates and lumacaftor; ivacaftor is a strong CYP3A inducer. Concomitant use of a cannabinoid product containing THC and CBD at an approximate 1:1 ratio with another strong CYP3A inducer decreased THC, 11-OH-THC, and CBD peak exposures by 36%, 87%, and 52% respectively.
DISCLAIMER: This drug information content is provided for informational purposes only and is not intended to be a substitute for professional medical advice, diagnosis, or treatment. Patients should always consult their physician with any questions regarding a medical condition and to obtain medical advice and treatment. Drug information is sourced from GSDD (Gold Standard Drug Database ) provided by Elsevier.
